Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome, Non-hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Conditions
Keywords
NHL, Non-Hodgkin Lymphoma, Haploidentical, Bone Marrow Transplant, Stem Cell Transplant, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome, Chronic Lymphocytic Leukemia, GVHD
Brief summary
Historically, the best results of allogeneic SCT have been obtained when the stem cell donor is a human leukocyte antigen (HLA)-matched sibling, however, this is only available for approximately 30 percent of patients in need for SCT. Alternative donor sources include matched unrelated donor utilizing the donor registry, cord blood transplant and mismatched donor transplant. A human leukocyte antigen (HLA)-haploidentical donor is one who shares, by common inheritance, exactly one HLA haplotype with the recipient, and includes the biologic parents, biologic children and full or half siblings. There is strong body of evidence supporting the use of haplo-SCT in patient who lack a matched sibling or unrelated donor with high rates of successful engraftment, effective Graft Versus Host Disease (GVHD) control and favorable outcomes comparative to those seen using other allograft sources, including HLA-matched sibling SCT. Furthermore, it provides a cost-efficient donor option in a timely manner especially for patients who need to proceed quickly to transplant due to concern of disease relapse/progression.
Detailed description
An open label, single-arm, single-center study to evaluate the safety, efficacy and feasibility of haplo-SCT as an alternative donor source for patients who lack a matched sibling/unrelated donor options. The choice of the chemotherapy treatment for transplantation will be up to the investigator. Post-transplant cyclophosphamide will serve as the backbone of the immunosuppression treatment to prevent GVHD. GVHD Prevention Treatment: Cyclophosphamide will be administered IV on Day 3 and Day 5 post transplant. Tacrolimus will be administered IV until patient can take it by mouth starting on day of transplant and continue approximately 100 days post-transplant. Mycophenolate mofetil will be administered IV until patient can take it by mouth starting on Day 1 post transplant until 28 days.
Interventions
DRUGCyclophosphamide
IV medication given for prevention of graft versus host disease.
DRUGTacrolimus
IV medication given for prevention of graft versus host disease.
DRUGMycophenolate mofetil
IV medication given for prevention of graft versus host disease.
A stem cell transplant that involves matching a patient's tissue type, specifically their human leukocyte antigen (HLA) tissue type, with that of a related donor.
Sponsors
Loyola University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
16 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Ages 16 years old and up * Performance Status 70 percent or above * Patients should have the following diseases: * Acute myelogenous leukemia (AML) * Acute lymphocytic leukemia or lymphoblastic lymphoma (ALL) * Transfusion dependent myelodysplastic syndrome (MDS) * Non-Hodgkin's Lymphoma (NHL) * Chronic lymphocytic leukemia (CLL) * Pulmonary function as measured by forced expiratory volume at one second (FEV1) and/or corrected diffusing capacity of lung for carbon monoxide (DLCO) at 60 percent of predicted or above * Left ventricular ejection fraction at 45 percent or above * If the donor-specific HLA antibodies (DSA) are positive, the patient must undergo a desensitization protocol resulting in undetectable DSA prior to day of transplant
Exclusion criteria
* Less than twenty-one days have elapsed since the subject's last radiation or chemotherapy prior to conditioning (except for hydroxyurea) * Uncontrolled bacterial, fungal or viral infections at time of study enrollment * Positive for HIV, human T-cell leukemia virus (HTLV-1) and/or Hepatitis C * Subjects with signs/symptoms of active central nervous system (CNS) disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Chimerism | 100 days | Blood test that measures amount of donor's cells |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Platelet engraftment | Day 60 | Blood test that measures the platelet count |
| Grade 3 to 4 acute graft-verus-host disease (GVHD) | 100 days | National Institutes of Health Acute Graft-Versus-Host Disease Grading and Form |
| Frequency and severity of chronic GVHD | 1 year | National Institutes of Health Chronic Graft-Versus-Host Disease Grading and Form |
| Neutrophil engraftment | Day 28 | Blood test that measures the white cell count |
| Survival status by patient contact | 3 years | Contact with patient by phone or doctor's visit |
| Immune reconstitution | 3 years | Blood work will be used to evaluate recovery of T and B cell count subset that assess cells which make antibodies to fight infections |
| Grade 3 through 5 Adverse Events | 2 years | Toxicities that are possibly, probably, and definitely related to study treatment according to NCI CTCAE Version 4 |
| Disease status with blast counts (immature blood cell count) above 5% | 3 years | Blood work and/or bone marrow biopsy will be used |
Countries
United States
Outcome results
None listed